{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:52:07Z","timestamp":1793609527405,"version":"4.5.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To investigate the noninferiority of relugolix compared with leuprorelin acetate in reducing heavy menstrual bleeding associated with uterine leiomyomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>In a double-blind, double-dummy trial, premenopausal women with uterine leiomyomas and heavy menstrual bleeding defined as a pictorial blood loss assessment chart score of at least 120 were randomized in a 1:1 ratio to relugolix (40 mg, oral, once daily) or leuprorelin acetate (1.88 mg or 3.75 mg, monthly injection) for 24 weeks. The primary endpoint was the proportion of patients with a total pictorial blood loss assessment chart score of less than 10 for weeks 6\u201312. Secondary endpoints included myoma and uterine volumes, and hemoglobin levels. A sample size of 144 patients per group (n=288) was estimated to provide at least 90% power to demonstrate noninferiority (prespecified noninferiority margin \u221215%; one-sided 0.025 level of significance).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      From March 2016 to September 2017, 281 patients were randomized (relugolix, n=139, leuprorelin n=142). Demographic and baseline characteristics were well balanced; mean pictorial blood loss assessment chart score was 254.3 in the relugolix group and 263.7 in the leuprorelin group. The proportion of patients with total pictorial blood loss assessment chart score of less than 10 for weeks 6\u201312 was 82.2% in the relugolix group and 83.1% in the leuprorelin group, demonstrating noninferiority of relugolix compared with leuprorelin (relugolix\u2212leuprorelin difference \u22120.9%; 95% CI: \u221210.10 to 8.35; prespecified noninferiority margin \u221215%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =.001). Reductions in myoma and uterine volumes and increases in hemoglobin levels were comparable in the two groups. Relugolix was associated with an earlier effect on menstrual bleeding than leuprorelin (pictorial blood loss assessment chart score of less than 10, 64.2% vs 31.7% [relugolix\u2212leuprorelin difference 32.5%; 95% CI: 20.95\u201344.13%] for weeks 2\u20136 and pictorial blood loss assessment chart score of 0, 52.6% vs 21.8% [30.7%; 95% CI: 19.45\u201342.00%] for weeks 2\u20136) and faster recovery of menses after treatment discontinuation (relugolix median [Q1, Q3], 37 days [32.0, 46.0]; leuprorelin median, 65 days [54.0, 77.0]). Adverse events and bone mineral density loss were similar between relugolix and leuprorelin treatment groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>In women with uterine leiomyomas, once-daily treatment with relugolix, an oral gonadotropin-releasing hormone antagonist, demonstrated noninferiority to monthly leuprorelin for improvement of heavy menstrual bleeding at 6\u201312 weeks of treatment, had a more rapid effect on menstrual bleeding, and was generally well tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CLINICAL TRIAL REGISTRATION:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, NCT02655237; JAPIC Clinical Trial Information, JapicCTI-163128.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>FUNDING SOURCE:<\/jats:title>\n                    <jats:p>Takeda Pharmaceutical Company Limited and an affiliate of NovaQuest Capital Management LLC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000003141","type":"journal-article","created":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T16:24:50Z","timestamp":1549988690000},"page":"423-433","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":99,"title":["Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas"],"prefix":"10.1097","volume":"133","author":[{"given":"Yutaka","family":"Osuga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Enya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentarou","family":"Kudou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Tanimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Hoshiai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261027","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1472-6874-12-6","article-title":"Prevalence, symptoms and management of uterine fibroids: an international internet-based survey of 21,746 women","volume":"12","author":"Zimmermann","year":"2012","journal-title":"BMC Womens Health"},{"key":"R2-20261027","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bpobgyn.2017.10.001","article-title":"Alternatives to hysterectomy: the burden of fibroids and the quality of life","volume":"46","author":"Fortin","year":"2018","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"R3-20261027","first-page":"CR24","article-title":"Hysterectomy surveillance in the United States, 1997 through 2005","volume":"14","author":"Merrill","year":"2008","journal-title":"Med Sci Monit"},{"key":"R4-20261027","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.ajog.2006.02.020","article-title":"Health care resource use for uterine fibroid tumors in the United States","volume":"195","author":"Flynn","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"R5-20261027","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ajog.2015.03.019","article-title":"The direct and indirect costs of uterine fibroid tumors: a systematic review of the literature between 2000 and 2013","volume":"213","author":"Soliman","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"R6-20261027","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1097\/JOM.0000000000001105","article-title":"Examining the relationship between symptomatic burden and self-reported productivity losses among patients with uterine fibroids in the United States","volume":"59","author":"Soliman","year":"2017","journal-title":"J Occup Environ Med"},{"key":"R7-20261027","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/01.AOG.0000136079.62513.39","article-title":"Uterine myomas: an overview of development, clinical features, and management","volume":"104","author":"Wallach","year":"2004","journal-title":"Obstet Gynecol"},{"key":"R8-20261027","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1701-2163(16)30582-5","article-title":"The management of uterine leiomyomas","volume":"25","author":"Lefebvre","year":"2003","journal-title":"J Obstet Gynaecol Can"},{"key":"R9-20261027","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1056\/NEJMcp1411029","article-title":"Clinical practice. Uterine fibroids","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"R10-20261027","doi-asserted-by":"crossref","first-page":"pii: E2188","DOI":"10.3390\/molecules22122188","article-title":"Recent development of non-peptide GnRH antagonists","volume":"22","author":"Tukun","year":"2017","journal-title":"Molecules"},{"key":"R11-20261027","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa1103180","article-title":"Ulipristal acetate versus leuprolide acetate for uterine fibroids","volume":"366","author":"Donnez","year":"2012","journal-title":"N Engl J Med"},{"key":"R12-20261027","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bpobgyn.2017.10.008","article-title":"The current place of medical therapy in uterine fibroid management","volume":"46","author":"Donnez","year":"2018","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"R13-20261027","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.tjog.2015.08.001","article-title":"Medical treatment for heavy menstrual bleeding","volume":"54","author":"Chen","year":"2015","journal-title":"Taiwan J Obstet Gynecol"},{"key":"R14-20261027","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1471-0528.1990.tb16249.x","article-title":"Assessment of menstrual blood loss using a pictorial chart","volume":"97","author":"Higham","year":"1990","journal-title":"Br J Obstet Gynaecol"},{"key":"R16-20261027","doi-asserted-by":"crossref","first-page":"e0149631","DOI":"10.1371\/journal.pone.0149631","article-title":"Medical therapies for uterine fibroids\u2014a systematic review and network meta-analysis of randomised controlled trials","volume":"11","author":"Gurusamy","year":"2016","journal-title":"PLoS One"},{"key":"R17-20261027","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/hae.12014","article-title":"Bleeding disorders, menorrhagia and iron deficiency: impacts on health-related quality of life","volume":"19","author":"Rae","year":"2013","journal-title":"Haemophilia"},{"key":"R19-20261027","first-page":"592","article-title":"Silencing Med12 gene reduces proliferation of human leiomyoma cells mediated via wnt\/beta-catenin signaling pathway","volume":"158","author":"Al-Hendy","year":"2017","journal-title":"Endocrinology"},{"key":"R20-20261027","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1126\/science.1208930","article-title":"MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas","volume":"334","author":"Makinen","year":"2011","journal-title":"Science"},{"key":"R21-20261027","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/his.12039","article-title":"Prevalence of MED12 mutations in uterine and extrauterine smooth muscle tumours","volume":"62","author":"Matsubara","year":"2013","journal-title":"Histopathology"},{"key":"R22-20261027","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/modpathol.2013.243","article-title":"MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma","volume":"27","author":"Bertsch","year":"2014","journal-title":"Mod Pathol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006250-201903000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:03:15Z","timestamp":1793109795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006250-201903000-00003"}},"subtitle":["A Randomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000003141","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"2018-06-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}